ライフサイエンスコーパス: tolerability

1 s of outcome regarding treatment efficacy or tolerability.

2 and improve disease severity with acceptable tolerability.

3 t could yield superior efficacy, safety, and tolerability.

4 rphine (10 mg/70 kg) in the clinic to ensure tolerability.

5 6-minute-walk distance (meters), safety, and tolerability.

6 An improved analog, MYCi975 showed better tolerability.

7 motherapy was given without signs of reduced tolerability.

8 mechanism which was likely to drive the poor tolerability.

9 free survival, overall survival, safety, and tolerability.

10 onotherapy with respect to both efficacy and tolerability.

11 nner while maintaining acceptable safety and tolerability.

12 nal symptoms as well as treatment safety and tolerability.

13 There were no reported differences in tolerability.

14 and also suggest good to moderate treatment tolerability.

15 ificant difference in IOP-lowering effect or tolerability.

16 ompared with placebo demonstrated safety and tolerability.

17 ith low pharmacokinetic variability and good tolerability.

18 mary objectives of the study were safety and tolerability.

19 ge of solvents while also showing high water tolerability.

20 ase with the aim to improve gastrointestinal tolerability.

21 ting PKDL is efficacious and safe, with high tolerability.

22 reporting clinical responses with acceptable tolerability.

23 rmation about treatment risks, benefits, and tolerability.

24 t they have only modest efficacy and limited tolerability(1,2).

25 multicenter pilot trial assessed the safety, tolerability, adherence, and pharmacodynamics of two dos

26 acilitate robust mRNA delivery with improved tolerability after single and repeated administrations.

27 retroviral therapy (ART) because of superior tolerability and a lower risk of resistance emergence.

28 We therefore examined the tolerability and activity of combined LEN/AZA administra

29 Recently, we reported safety, tolerability and antibody response data from an ongoing

30 in-class DARPin drug candidate with suitable tolerability and appropriate pharmacokinetic properties

31 s antitumor T-cell epitopes, with a focus on tolerability and avoidance of severe autoimmunity, offer

32 the inpatient setting due its better rate of tolerability and comparable bowel cleanliness when compa

33 g in antibody variants with improved in vivo tolerability and developability.

34 Ophthalmic examinations, OCT, and ocular tolerability and discomfort assessments were conducted;

35 The authors examined the tolerability and effectiveness of DBS in an open study o

36 ese compounds, MYCi975, has shown remarkable tolerability and efficacy in vivo and is associated with

37 We investigated the tolerability and efficacy of 2 exercise training dose re

38 luation Program-sponsored trial assessed the tolerability and efficacy of a gemcitabine-eribulin comb

39 Here, we examine the tolerability and efficacy of non-selective HTT lowering

40 there is still an unmet need to improve the tolerability and efficacy of this therapy.

41 The tolerability and efficacy of venetoclax in combination w

42 postoperative adjuvant chemotherapy impairs tolerability and feasibility and does not improve effica

43 We previously reported the tolerability and immunogenicity 1 month after intramuscu

44 Here we report the available safety, tolerability and immunogenicity data from an ongoing pla

45 A first tolerability and immunogenicity study, including a boost

46 ally useful combination of cleansing, safety/tolerability and low consumption volume: 1 L preparation

47 Primary objectives were evaluation of safety/tolerability and pharmacokinetics; antitumor activity wa

48 T(reg) cell therapy have shown feasibility, tolerability and potential efficacy in these disease set

49 The tolerability and preliminary activity for the two most a

50 ion study (NCT02027961) investigated safety, tolerability and preliminary efficacy of durvalumab (ant

51 ontrolled trial was performed to compare the tolerability and radical curative efficacy of 7-day vers

52 On the basis of tolerability and receptor occupancy studies that showed

53 of an intermittent 5/7-day schedule improved tolerability and reduced frequency and severity of neutr

54 el of novel object recognition with improved tolerability and reduced vascular toxicity over earlier

55 Assessments included vaccine tolerability and safety in women and infants, and RSV-sp

56 seizure medications have shown advantages in tolerability and safety, particularly in the treatment o

57 Functional Rating Scale-Revised (ALSFRS-R), tolerability and safety.

58 dition of NAPs to TDF + pegIFN did not alter tolerability and significantly increased rates of HBsAg

59 ave sub-optimal pharmacokinetics, stability, tolerability and/or efficacy.

60 Primary endpoints were safety and tolerability, and 12-week disease control rate.

61 hieves the optimal balance between efficacy, tolerability, and acceptability in the acute treatment o

62 In this study, we assessed the compliance, tolerability, and acceptability of the 3-day atovaquone/

63 le-dose study was done to assess the safety, tolerability, and activity of trastuzumab deruxtecan in

64 le-dose study was done to assess the safety, tolerability, and activity of trastuzumab deruxtecan in

65 We aimed to assess the safety, tolerability, and antitumour activity of avapritinib, a

66 We aimed to evaluate the safety, tolerability, and antitumour activity of margetuximab pl

67 The primary objectives were safety and tolerability, and antitumour response.

68 Excellent safety, tolerability, and comfort profile supports this new CsA

69 senting the first human trial of the safety, tolerability, and cutaneous immune cell trafficking chan

70 ear-infrared laser vaccine adjuvant: safety, tolerability, and cutaneous immune cell trafficking.

71 imary endpoints of the study were safety and tolerability, and determination of the maximum tolerated

72 aim of this study was to assess the safety, tolerability, and effects on renal function as well as t

73 to examine a range of oral doses for safety, tolerability, and efficacy for the preventive treatment

74 The safety, tolerability, and efficacy of a single IVT brolucizumab

75 We evaluated the safety, tolerability, and efficacy of ado-trastuzumab emtansine

76 an open-label trial to evaluate the safety, tolerability, and efficacy of ledipasvir and sofosbuvir

77 his study was designed to assess the safety, tolerability, and efficacy of pamrevlumab (FG-3019), a f

78 a low-resource setting, we assessed safety, tolerability, and efficacy within a prospective cohort o

79 idosis was designed to determine the safety, tolerability, and hematologic and clinical response.

80 In this phase 2 study, we explored safety, tolerability, and immunogenicity in older US adults of a

81 This study compared the safety, tolerability, and immunogenicity of a newly developed, t

82 ry objectives were evaluation of the safety, tolerability, and immunogenicity of ExPEC4V and determin

83 e 1 study (VAC52150EBL1004) assessed safety, tolerability, and immunogenicity of heterologous 2-dose

84 first clinical trial to evaluate the safety, tolerability, and immunogenicity of lower doses of influ

85 This phase 2 study evaluated safety, tolerability, and immunogenicity of PCV20 in adults with

86 In this study, we evaluated the safety, tolerability, and immunogenicity of shorter, simpler reg

87 This study (WRAIR-2274) assessed the safety, tolerability, and immunogenicity of the GLS-5300 MERS co

88 Early data confirm safety, tolerability, and immunogenicity of typhoid conjugate va

89 im of this work was to determine the safety, tolerability, and impact on mucosal/stool microbiota and

90 high potency and barrier to resistance, good tolerability, and low cost, but there is uncertainty ove

91 Primary objectives were safety, tolerability, and maximum tolerated dose; secondary obje

92 Both candidates had acceptable tolerability, and no serious adverse events occurred dur

93 Secondary end points included response, tolerability, and patient-reported endocrine symptoms.

94 ose study (NCT02720263) assessed the safety, tolerability, and pharmacodynamics of ASP4345 in patient

95 -human study was conducted to assess safety, tolerability, and pharmacokinetic (PK) and pharmacodynam

96 ical trial we aimed to determine the safety, tolerability, and pharmacokinetic profile of the broadly

97 I study was conducted to assess the safety, tolerability, and pharmacokinetics of MP0250 in 45 patie

98 bo-controlled study investigated the safety, tolerability, and pharmacokinetics of nilotinib, and mea

99 e-1 evaluation in healthy humans for safety, tolerability, and pharmacokinetics paved the way for its

100 Phase-1 evaluation for safety, tolerability, and pharmacokinetics, and long-term safety

101 Primary endpoints were DSM265 safety, tolerability, and pharmacokinetics.

102 Efficacy, safety, tolerability, and practical considerations, including po

103 The authors examined the feasibility, tolerability, and preliminary efficacy of Stanford Accel

104 Treatment efficacy, tolerability, and safety profiles differed among treatme

105 y end points were patient-reported outcomes, tolerability, and safety.

106 es of symptoms, neurocognition, functioning, tolerability, and safety.

107 nd clinical studies evaluating its efficacy, tolerability, and safety.

108 d reaction conditions, good functional group tolerability, and scalability.

109 ral initiation, drug-drug interactions, drug tolerability, and the prevention and treatment of tuberc

110 at the maximum administered dose, safety and tolerability, and the proportion of patients with object

111 We tested the safety, tolerability, and visual function effects of oral NAC in

112 secondary objectives were to assess safety, tolerability, antitumor efficacy, pharmacokinetics, and

113 of PCSK9i on LDL and Lp(a) reduction and on tolerability are applicable to a real-world cohort.

114 s, even with proper adherence and acceptable tolerability, are not effective for nearly one third of

115 weeks at 700 mg is feasible, with comparable tolerability as daily administration.

116 rimary objective of the study was safety and tolerability assessed by adverse events, changes in left

117 The primary endpoint was safety and tolerability, assessed in all children who received at l

118 The primary endpoints were safety and tolerability, assessed in all patients enrolled in the s

119 The primary endpoints were safety and tolerability, assessed in the safety population (patient

120 s that are required for in vivo efficacy and tolerability assessment(10-13).

121 After tolerability assessment, 50 demonstrated a promising in

122 CyclASol showed efficacy, safety, and tolerability at 2 concentrations in moderate-to-severe D

123 rst-in-humans study investigated the safety, tolerability, biodistribution, and radiation dosimetry o

124 resectable CC is feasible with an acceptable tolerability but is not associated with an increased maj

125 enhanced treatment for obesity with improved tolerability compared with liraglutide monotherapy.

126 No new safety or tolerability concerns emerged in this study.

127 ted on the basis of prespecified HbA(1c) and tolerability criteria.

128 We report the first real-life tolerability data in 50 patients with hematologic malign

129 Primary endpoints were safety and tolerability, determination of maximum tolerated dose in

130 nstrate favourable pharmacokinetics, safety, tolerability, dose-dependent PK/PD relationships and hig

131 r greater reduction in depression severity), tolerability (dropouts due to adverse effects), and acce

132 (Safety, Tolerability & Efficacy on LDL-C of Evolocumab in Subjec

133 Safety and tolerability findings were consistent with the full stud

134 lderly patients with STS and offers superior tolerability for hematologic toxicity.

135 that are particularly relevant to treatment tolerability for patients living with indolent disease.

136 clinical efficacy with acceptable safety and tolerability in a phase 1 trial.

137 We assessed safety and tolerability in all participants who received study drug

138 absence of neutropenia and improved overall tolerability in multiple rodent models.

139 demonstrated efficacy as well as safety and tolerability in parallel phase 2 studies; however, its p

140 tabine was clinically active with acceptable tolerability in patients with intermediate-risk and high

141 e 1 study that aims to assess its safety and tolerability in patients with mIDH1 solid tumours.

142 has durable clinical activity and favourable tolerability in patients with relapsed or refractory chr

143 n given with obinutuzumab and its safety and tolerability in patients with relapsed/refractory (R/R)

144 vedotin (pina) showed clinical activity and tolerability in phase 1 trials.

145 ody of evidence on its efficacy, safety, and tolerability in the preclinical and clinical setting.

146 tor that demonstrated favorable efficacy and tolerability in the treatment of tardive dyskinesia in p

147 escalation part of the study were safety and tolerability, including the occurrence of dose-limiting

148 Outcomes were tolerability, inflammatory, and immunologic measures, an

149 Evaluation of tolerability is increasingly relevant for patients with

150 No serious safety or tolerability issues have been identified in the trials o

151 ealth status, and exacerbation rate, with no tolerability issues reported.

152 No new or unexpected safety and tolerability issues were identified and there were no tr

153 ences the allocation of chemotherapy and its tolerability; it also affects patient survival.

154 rs, adverse events, and CHIKV infection) and tolerability (local and systemic reactogenicity) of the

155 in vivo pharmacokinetic (PK) properties and tolerability mark these inhibitors as advanced preclinic

156 The primary outcomes were safety, tolerability, maximum tolerated dose, and recommended ph

157 Primary success rates, tolerability, morbidity, dose rate of radiation, and 30-

158 Secondary outcomes included tolerability, ocular surface health, quality of life, di

159 parallel design, we tested the efficacy and tolerability of 4-wk intranasal OXT treatment (24 Intern

160 rolled trial to assess the effectiveness and tolerability of a budesonide orodispersible tablet (BOT)

161 on standard practice in assessing safety and tolerability of a new chemical entity.

162 ial was to compare the efficacy, safety, and tolerability of a novel orally disintegrating tablet for

163 study objective was dose-related safety and tolerability of ABI-H0731 in healthy volunteers and in p

164 tension study, assessed long-term safety and tolerability of adjunctive BUP/SAM treatment in these pa

165 aimed to evaluate the safety, efficacy, and tolerability of adjunctive cenobamate in patients with u

166 lts so far point to feasibility, safety, and tolerability of administration of islet autoantigens and

167 aimed to evaluate the accuracy, safety, and tolerability of an intensive monitoring strategy designe

168 Safety and tolerability of analytical treatment interruptions (ATIs

169 extension study were to assess the long-term tolerability of asfotase alfa, defined as the number of

170 onal) raised some concerns on the safety and tolerability of BACE1 inhibition.

171 describe the treatment outcomes, safety, and tolerability of bedaquiline in our case series.

172 We describe treatment outcomes, safety, and tolerability of bedaquiline in our case series.

173 m was to determine the efficacy, safety, and tolerability of berotralstat in patients with HAE over a

174 We assessed the efficacy, safety and tolerability of bictegravir, emtricitabine, and tenofovi

175 xamine the longer-term efficacy, safety, and tolerability of bictegravir, emtricitabine, and tenofovi

176 We aimed to investigate the safety and tolerability of BIIB092 in individuals with progressive

177 We aimed to assess the safety, efficacy, and tolerability of bimagrumab-a fully human monoclonal anti

178 y further assessed the efficacy, safety, and tolerability of cariprazine in bipolar I depression.

179 will be crucial to our understanding of the tolerability of chronically administered therapies in pa

180 imary objective was to assess the safety and tolerability of combining trilaciclib with gemcitabine a

181 Little is known about the efficacy and tolerability of continuing antipsychotic medication for

182 imary objective was to assess the safety and tolerability of CYP-001, while the secondary objectives

183 The high efficacy and tolerability of DAA therapy has also created a rationale

184 We examined the efficacy and tolerability of dapagliflozin in relation to background

185 m was to examine long-term effectiveness and tolerability of DBS and its impact on functioning and we

186 ies are expected to enhance the efficacy and tolerability of DBS.

187 ed by the accessibility, cost, efficacy, and tolerability of delivery systems.

188 his study aimed to evaluate the efficacy and tolerability of different GA dosing regimens in patients

189 following: (1) comparative effectiveness and tolerability of different oral 5-ASA therapies (sulfalsa

190 We investigated the efficacy and tolerability of fremanezumab, a fully humanised CGRP ant

191 We aimed to compare the efficacy and tolerability of fully oral rifampicin 10 mg/kg plus clar

192 An evaluation of the efficacy and tolerability of generic prostaglandin analogues (PGAs) c

193 This study aimed to determine safety and tolerability of iadademstat as monotherapy in patients w

194 seases, including method of delivery, doses, tolerability of intrathecally delivered antisense drugs,

195 mal formulation was developed to improve the tolerability of intravenous amphotericin B, while optimi

196 The primary outcomes were safety and tolerability of islatravir and change from baseline in H

197 dy was to evaluate the efficacy, safety, and tolerability of lacosamide as a potential treatment for

198 The efficacy, safety, and tolerability of lumacaftor and ivacaftor are established

199 to compare the real-world effectiveness and tolerability of newer antipsychotics with those of tradi

200 was to characterise the long-term safety and tolerability of nintedanib in patients with idiopathic p

201 ck record of desensitization, the safety and tolerability of OIT has remained a question.

202 t gain, and to assess the overall safety and tolerability of olanzapine plus samidorphan.

203 Safety and tolerability of oral semaglutide were similar to subcuta

204 The APOLLO study assessed the efficacy and tolerability of patisiran in patients with hATTR amyloid

205 summarizes the clinical efficacy, safety and tolerability of pitolisant in treating the symptoms of n

206 study was to assess the long-term safety and tolerability of PRM-151, which were assessed by analysin

207 We assessed safety and tolerability of rAAV1-PG9DP, a recombinant AAV1 vector e

208 The primary endpoint was the safety and tolerability of ramucirumab in combination with pembroli

209 derate UC; (4) comparative effectiveness and tolerability of rectal 5-ASA and corticosteroid formulat

210 Primary outcomes were the safety and tolerability of REP 2139-Mg or REP 2165-Mg in combinatio

211 1b trial of limited duration, the safety and tolerability of SER-287 were similar to placebo.

212 eatment-specific items as well as to compare tolerability of SRFA to transarterial chemoembolization

213 o assess the feasibility, acceptability, and tolerability of storytelling among bereaved surrogates i

214 med to investigate the efficacy, safety, and tolerability of switching to this regimen compared with

215 The safety and tolerability of the 231 VCEs ingested was excellent, wit

216 velopment has improved efficacy, safety, and tolerability of the class.

217 e first translational evidence of safety and tolerability of the ghrelin receptor inverse agonist PF-

218 ng that subcutaneous bortezomib improves the tolerability of the panobinostat plus bortezomib plus de

219 To improve sampling methods and tolerability of the procedure, we optimized a balloon de

220 ular risk, but always considering individual tolerability of the proposed goal.

221 Tolerability of the prototype was demonstrated in awake,

222 arcinoma while also assessing the safety and tolerability of the radiotracer.

223 A detailed assessment of safety and tolerability of the study drugs was done in all patients

224 brotic activities may improve the safety and tolerability of the therapy.

225 The primary endpoint was the safety and tolerability of the two dosing regimens of benralizumab

226 onses at weeks 28, 52, and 72 and safety and tolerability of the vaccine regimens for 28 days after t

227 imary objective was to assess the safety and tolerability of these regimens.

228 Primary outcomes were safety and tolerability of these vaccination regimens and cellular

229 imaging, as well as to assess its safety and tolerability of this new tau PET tracer.

230 imaging, as well as to assess the safety and tolerability of this new tau PET tracer.

231 n and reporting of toxicity that capture the tolerability of treatment to the patient are imperative.

232 Tolerability of treatments for multiple myeloma can depe

233 015-18) evaluating the efficacy, safety, and tolerability of triple artemisinin combination therapies

234 n BR dose intensity may improve efficacy and tolerability of VEN + BR, while VEN + R data warrant fur

235 Given the safety and tolerability of VNS therapy, these findings suggest that

236 The primary outcome was the safety and tolerability of VRC07-523LS, assessed by dose, route, an

237 There was no significant imbalance in tolerability or safety events between dapagliflozin and

238 There were no new tolerability or safety signals in adolescents.

239 e past 10 years owing to lack of efficacy or tolerability, or both.

240 Findings on secondary efficacy and safety/tolerability outcome measures in Asian patients were als

241 Safety and tolerability outcomes were assessed by evaluating local

242 Safety, tolerability, pharmacodynamic effects of cilofexor (seru

243 Therefore, we evaluated the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD)

244 We aimed to establish the safety, tolerability, pharmacokinetic profile, and antitumour ac

245 The study evaluated the safety, tolerability, pharmacokinetic, and pharmacodynamic prope

246 intravenous immunoglobulin (IVIg) on safety, tolerability, pharmacokinetics (PK), and pharmacodynamic

247 study of this kind, investigates the safety, tolerability, pharmacokinetics, and clinical activity of

248 , a phase 1 study to evaluate mAb114 safety, tolerability, pharmacokinetics, and immunogenicity.

249 We assessed the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of

250 , placebo-controlled study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of

251 o-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of

252 We report the safety, tolerability, pharmacokinetics, pharmacodynamics, and pr

253 ial designed to determine vaccine safety and tolerability (primary outcomes) and recurrence-free surv

254 The vaccine had an acceptable tolerability profile and induced rapid, robust humoral i

255 mains may result in a different efficacy and tolerability profile compared with DbBi.

256 e compared with EFV or DRV+r and a favorable tolerability profile compared with EFV.

257 The non-inferior efficacy and similar tolerability profile of dolutegravir plus lamivudine to

258 kely contributes to the favorable safety and tolerability profile of lumateperone with reduced risk f

259 The two regimens with the better tolerability profile on the basis of predefined criteria

260 ith a low incidence of PTDM and a manageable tolerability profile over 24 weeks of treatment.

261 that nintedanib has a manageable safety and tolerability profile over long-term use, with no new saf

262 , at every time point assessed and an ocular tolerability profile similar to that of netarsudil alone

263 ellent in vivo efficacy and a very desirable tolerability profile, 5a (branebrutinib, BMS-986195) has

264 in AD symptoms and an acceptable safety and tolerability profile, thereby providing evidence for tar

265 free cortisol, with an acceptable safety and tolerability profile.

266 reatment, which has an acceptable safety and tolerability profile.

267 nist with an apparently favorable safety and tolerability profile.

268 rmone antagonist with superior endocrine and tolerability profiles and positive outcomes for non-meta

269 T-cell responses with acceptable safety and tolerability profiles in M.tb-infected and M.tb-uninfect

270 ppear to underpin the favorable activity and tolerability profiles of effective systemic administrati

271 The safety and tolerability profiles of the two antibiotics were simila

272 Tolerability profiles were comparable between arms.

273 xible dose adjustment, based on efficacy and tolerability, provided superior glycaemic control and we

274 Secondary outcomes included tolerability, safety, adverse events, isokinetic muscula

275 Key end points were tolerability, safety, response rates, duration of respon

276 s included neutrophil chemotaxis, safety and tolerability, Sequential Organ Failure Assessment score,

277 A representative was advanced into a dog tolerability study where it was found to be well tolerat

278 The primary outcomes were the tolerability, systemic exposure, maximum tolerated dose,

279 In a preliminary assessment of tolerability, the anti-CLDN18.2 diabody (0.34 mg/kg) did

280 objectives were to determine the safety and tolerability, the non-tolerated dose, maximum tolerated

281 ination therapy showed acceptable safety and tolerability; there were no dose-limiting toxicities in

282 ug and exhibit greater efficacy and expanded tolerability, thereby addressing a longstanding objectiv

283 ased on considerations of risk reduction and tolerability was appropriate.

284 Tolerability was similar to placebo, with no safety conc

285 Tolerability was similar to that of placebo, and no unex

286 The main outcomes to assess safety and tolerability were adverse event recordings.

287 Safety and tolerability were assessed by clinical and laboratory cr

288 Efficacy and tolerability were assessed retrospectively.

289 Safety and tolerability were compared descriptively across treatmen

290 Safety and tolerability were good with both treatments.

291 Safety and tolerability were manageable.

292 Safety and tolerability were similar to placebo.

293 free agent over time, significantly improved tolerability when compared to the parent LRAs.

294 Primary endpoints were safety and tolerability, which were assessed in all dosed patients.

295 fine-tuned to navigate in vivo exposure and tolerability while driving therapeutic efficacy.

296 from DNA damage and toxicity, thus improving tolerability while preserving efficacy in ovarian cancer

297 The primary end point was the safety and tolerability, while secondary end points were clinical o

298 Primary endpoints were safety and tolerability, with exploratory efficacy and immunology e

299 Our primary endpoints were safety and tolerability, with pharmacokinetic and anti-drug antibod

300 The primary outcome was safety and tolerability, with secondary objectives assessing virus-